Trial Profile
A study evaluating differences in characteristics of patients receiving PCSK9 inhibitors versus those who did not.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Dec 2016
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary) ; Evolocumab (Primary)
- Indications Atherosclerosis; Hypercholesterolaemia
- Focus Therapeutic Use
- 21 Dec 2016 New trial record
- 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association